Market Price

70.12 

-0.64 -0.9%

as of Dec 17 '18

52 Week Range:

55.42 74.92


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon. Its Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; benchtop systems and rapid tests in the areas of infectious diseases; molecular point-of-care test systems for influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The company's Nutritional Products segment provides pediatric and adult nutritional products. Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Equity (BVPS) 11.47
11.27
14.73
14.47
15.67
16.95
15.31
15.18
14.34
14.11
18.37
growth rate -1.7% 30.7% -1.8% 8.3% 8.2% -9.7% -0.9% -5.5% -1.6% 30.2%
Earnings BIT 4,470.00
5,860.00
7,190.00
5,710.00
5,200.00
6,260.00
2,520.00
2,888.00
2,962.00
3,277.00
2,940.00
growth rate 31.1% 22.7% -20.6% -8.9% 20.4% -59.7% 14.6% 2.6% 10.6% -10.3%
Avg.PE 24.27
17.61
14.64
16.18
18.62
17.48
25.58
31.23
13.50
48.75
219.78
growth rate -27.4% -16.9% 10.5% 15.1% -6.1% 46.3% 22.1% -56.8% 261.1% 350.8%
ROA 9.50
11.88
12.12
8.27
7.90
9.35
4.68
5.42
10.72
2.98
0.74
growth rate 25.1% 2.0% -31.8% -4.5% 18.4% -50.0% 15.8% 97.8% -72.2% -75.2%
ROE 22.66
27.69
28.49
20.45
20.20
23.31
9.93
9.78
20.70
6.71
1.85
growth rate 22.2% 2.9% -28.2% -1.2% 15.4% -57.4% -1.5% 111.7% -67.6% -72.4%
ROIC 14.08
17.47
17.74
12.38
12.65
14.82
6.74
7.64
15.01
4.53
1.18
growth rate 24.1% 1.6% -30.2% 2.2% 17.2% -54.5% 13.4% 96.5% -69.8% -74.0%
Cur. Ratio 1.54
1.47
1.79
1.29
1.54
2.36
2.02
1.45
1.54
4.02
2.26
growth rate -4.6% 21.8% -27.9% 19.4% 53.3% -14.4% -28.2% 6.2% 161.0% -43.8%
Quick Ratio 0.85
0.91
1.26
0.73
1.02
1.72
1.27
0.76
1.04
3.31
1.67
growth rate 7.1% 38.5% -42.1% 39.7% 68.6% -26.2% -40.2% 36.8% 218.3% -49.6%
Leverage 2.23
2.43
2.29
2.66
2.47
2.52
1.71
1.92
1.94
2.56
2.47
growth rate 9.0% -5.8% 16.2% -7.1% 2.0% -32.1% 12.3% 1.0% 32.0% -3.5%
Balance Sheet Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Acct.Receivable 0.00
6,541.90
7,184.00
10,384.46
10,599.00
6,514.00
3,586.00
3,418.00
3,248.00
5,249.00
growth rate 9.8% 44.6% 2.1% -38.5% -45.0% -4.7% -5.0% 61.6%
Acct.Payable 12,105.47
10,889.00
5,948.00
1,064.00
1,081.00
1,178.00
2,402.00
growth rate -10.1% -45.4% -82.1% 1.6% 9.0% 103.9%
Cur.Assets 17,042.60
23,313.90
22,317.50
23,768.77
31,323.00
19,247.00
13,556.00
14,155.00
26,776.00
20,147.00
growth rate 36.8% -4.3% 6.5% 31.8% -38.6% -29.6% 4.4% 89.2% -24.8%
Total Assets 42,419.20
52,416.60
60,573.90
60,276.89
67,235.00
42,953.00
41,207.00
41,247.00
52,666.00
76,250.00
growth rate 23.6% 15.6% -0.5% 11.5% -36.1% -4.1% 0.1% 27.7% 44.8%
Cash 4,112.00
8,809.30
3,648.40
6,812.82
10,802.00
3,475.00
4,063.00
5,001.00
18,620.00
9,407.00
growth rate 114.2% -58.6% 86.7% 58.6% -67.8% 16.9% 23.1% 272.3% -49.5%
Inventory 2,775.80
3,264.90
3,188.70
3,284.25
3,793.00
2,693.00
2,643.00
2,599.00
2,434.00
3,601.00
growth rate 17.6% -2.3% 3.0% 15.5% -29.0% -1.9% -1.7% -6.4% 48.0%
Cur.Liabilities 11,591.90
13,049.50
17,262.40
15,480.23
13,280.00
9,507.00
10,467.00
9,186.00
6,660.00
8,912.00
growth rate 12.6% 32.3% -10.3% -14.2% -28.4% 10.1% -12.2% -27.5% 33.8%
Liabilities 24,939.70
29,561.00
37,897.10
35,837.06
40,514.00
17,782.00
19,568.00
19,921.00
31,949.00
45,152.00
growth rate 18.5% 28.2% -5.4% 13.1% -56.1% 10.0% 1.8% 60.4% 41.3%
LT Debt 9,490.00
8,713.30
11,266.30
12,523.50
12,039.82
18,085.00
3,388.00
3,393.00
5,871.00
20,681.00
27,210.00
growth rate -8.2% 29.3% 11.2% -3.9% 50.2% -81.3% 0.2% 73.0% 252.3% 31.6%
Equity 17,778.54
17,479.60
22,855.60
22,676.80
24,439.83
26,721.00
25,171.00
21,526.00
21,211.00
20,538.00
30,897.00
growth rate -1.7% 30.8% -0.8% 7.8% 9.3% -5.8% -14.5% -1.5% -3.2% 50.4%
Common Shares 1,560.00
1,564.00
1,555.00
1,556.00
1,567.00
1,592.00
1,574.00
1,527.00
1,506.00
1,483.00
1,749.00
growth rate 0.3% -0.6% 0.1% 0.7% 1.6% -1.1% -3.0% -1.4% -1.5% 17.9%
Cash Flow Statement Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Capital Expenditures 1,656.21
1,287.70
1,089.00
1,015.10
1,491.00
1,795.00
1,145.00
1,077.00
1,110.00
1,121.00
1,135.00
growth rate -22.3% -15.4% -6.8% 46.9% 20.4% -36.2% -5.9% 3.1% 1.0% 1.3%
Cash Dividends 1,959.15
2,174.30
2,414.50
2,671.50
2,938.00
3,183.00
882.00
1,342.00
1,443.00
1,539.00
1,849.00
growth rate 11.0% 11.1% 10.6% 10.0% 8.3% -72.3% 52.2% 7.5% 6.7% 20.1%
Cash From OA 5,183.84
6,994.60
7,275.20
8,736.00
8,970.00
9,314.00
3,324.00
3,675.00
2,966.00
3,203.00
5,570.00
growth rate 34.9% 4.0% 20.1% 2.7% 3.8% -64.3% 10.6% -19.3% 8.0% 73.9%
FCF per Share 2.26
3.88
3.97
4.96
5.36
4.72
1.25
1.93
1.47
1.22
2.37
growth rate 71.7% 2.3% 24.9% 8.1% -11.9% -73.5% 54.4% -23.8% -17.0% 94.3%
Sale Purchase of Stock 892.00
-514.00
-1,210.00
429.00
314.00
248.00
350.00
growth rate -100.0% 0.0% 100.0% -26.8% -21.0% 41.1%
FCF 3,528.00
6,056.00
6,186.00
7,721.00
7,479.00
7,519.00
2,179.00
2,598.00
1,856.00
2,082.00
4,435.00
growth rate 71.7% 2.2% 24.8% -3.1% 0.5% -71.0% 19.2% -28.6% 12.2% 113.0%
Income Statement Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Sales 25,910.00
29,527.60
30,764.70
35,166.70
21,407.00
19,050.00
19,657.00
20,247.00
20,405.00
20,853.00
27,390.00
growth rate 14.0% 4.2% 14.3% -39.1% -11.0% 3.2% 3.0% 0.8% 2.2% 31.4%
Op.Income 5,693.80
6,235.70
6,087.60
1,126.00
237.00
1,988.00
2,888.00
2,962.00
3,277.00
2,940.00
growth rate 9.5% -2.4% -81.5% -79.0% 738.8% 45.3% 2.6% 10.6% -10.3%
IBT 5,856.30
7,193.80
5,712.80
1,236.00
-220.00
2,041.00
2,518.00
3,183.00
1,413.00
2,231.00
growth rate 22.8% -20.6% -78.4% -100.0% 100.0% 23.4% 26.4% -55.6% 57.9%
Net Income 4,880.70
5,745.80
4,626.20
1,126.00
237.00
1,988.00
2,284.00
4,423.00
1,400.00
477.00
growth rate 17.7% -19.5% -75.7% -79.0% 738.8% 14.9% 93.7% -68.4% -65.9%
EPS 2.31
3.12
3.69
2.96
3.01
3.72
1.62
1.49
2.92
0.94
0.27
growth rate 35.1% 18.3% -19.8% 1.7% 23.6% -56.5% -8.0% 96.0% -67.8% -71.3%
Gross Profit 14,492.19
16,915.50
17,555.40
20,501.50
11,390.00
10,151.00
10,464.00
11,056.00
11,676.00
11,838.00
15,972.00
growth rate 16.7% 3.8% 16.8% -44.4% -10.9% 3.1% 5.7% 5.6% 1.4% 34.9%
R&D 2,688.80
2,913.70
3,724.40
1,512.00
1,461.00
1,371.00
1,286.00
1,371.00
1,358.00
2,158.00
growth rate 8.4% 27.8% -59.4% -3.4% -6.2% -6.2% 6.6% -1.0% 58.9%

Quarterly Statements

Item Name Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Earnings BIT 830.00
1,181.00
685.00
882.00
995.00
growth rate 42.3% -42.0% 28.8% 12.8%
Balance Sheet Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Acct.Receivable 4,800.00
5,249.00
5,356.00
5,192.00
5,271.00
growth rate 9.4% 2.0% -3.1% 1.5%
Acct.Payable 1,858.00
2,402.00
2,476.00
2,503.00
2,730.00
growth rate 29.3% 3.1% 1.1% 9.1%
Cur.Assets 21,377.00
20,147.00
14,964.00
14,122.00
18,196.00
growth rate -5.8% -25.7% -5.6% 28.9%
Total Assets 72,248.00
76,250.00
70,908.00
68,415.00
71,637.00
growth rate 5.5% -7.0% -3.5% 4.7%
Cash 11,012.00
9,407.00
3,857.00
3,065.00
7,369.00
growth rate -14.6% -59.0% -20.5% 140.4%
Inventory 3,483.00
3,601.00
3,826.00
3,714.00
3,781.00
growth rate 3.4% 6.3% -2.9% 1.8%
Cur.Liabilities 7,935.00
8,912.00
9,010.00
8,951.00
12,776.00
growth rate 12.3% 1.1% -0.7% 42.7%
Liabilities 40,030.00
45,152.00
39,307.00
37,641.00
40,739.00
growth rate 12.8% -13.0% -4.2% 8.2%
LT Debt 23,363.00
27,210.00
21,353.00
20,053.00
19,556.00
growth rate 16.5% -21.5% -6.1% -2.5%
Equity 32,032.00
30,897.00
31,399.00
30,577.00
30,705.00
growth rate -3.5% 1.6% -2.6% 0.4%
Common Shares 23,118.00
23,206.00
23,223.00
23,317.00
23,428.00
growth rate 0.4% 0.1% 0.4% 0.5%
Cash Flow Statement Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Capital Expenditures 263.00
275.00
275.00
298.00
354.00
growth rate 4.6% 0.0% 8.4% 18.8%
Cash Dividends 463.00
491.00
491.00
494.00
494.00
growth rate 6.1% 0.0% 0.6% 0.0%
Cash From OA 2,005.00
1,108.00
1,108.00
1,244.00
2,183.00
growth rate -44.7% 0.0% 12.3% 75.5%
Sale Purchase of Stock 89.00
137.00
137.00
33.00
growth rate 53.9% 0.0% -75.9%
FCF 1,742.00
833.00
833.00
946.00
1,829.00
growth rate -52.2% 0.0% 13.6% 93.3%
Income Statement Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Sales 6,829.00
7,589.00
7,390.00
7,767.00
7,656.00
growth rate 11.1% -2.6% 5.1% -1.4%
Op.Income 830.00
1,181.00
685.00
882.00
995.00
growth rate 42.3% -42.0% 28.8% 12.8%
IBT 626.00
574.00
431.00
777.00
718.00
growth rate -8.3% -24.9% 80.3% -7.6%
Net Income 603.00
-828.00
418.00
733.00
563.00
growth rate -100.0% 100.0% 75.4% -23.2%
EPS
growth rate
Gross Profit 3,992.00
4,460.00
4,366.00
4,485.00
4,490.00
growth rate 11.7% -2.1% 2.7% 0.1%
R&D 562.00
523.00
579.00
575.00
574.00
growth rate -6.9% 10.7% -0.7% -0.2%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

E (23.31)

YOY Growth Grade:

E (27.95)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 145.23 141.09 22.56
EPS / Growth -0.2% 0.50 11.8%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 11.7%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.0% 8.1% 8.1%
Future PE 2.00 19.42 19.42
Future EPS 0.55 1.09 1.09
Value Price
MOS %
0.27
-99.6%
5.22
-92.6%
5.22
-92.6%
MOS Price 0.14 2.61 2.61
IRT 87.85 31.33 31.33

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.